Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 14 Mar 23 EFFECT Notice of effectiveness
- 9 Mar 23 POS AM Prospectus update (post-effective amendment)
- 20 Oct 20 424B3 Prospectus supplement
- 20 Oct 20 EFFECT Notice of effectiveness
- 30 Sep 20 S-4/A Registration of securities issued in business combination transactions (amended)
-
28 Aug 20 S-4 Registration of securities issued in business combination transactions
FSTX similar filings
Filing view
External links
Exhibit 99.8
August 28, 2020
Spring Bank Pharmaceuticals, Inc.
35 Parkwood Drive, Suite 210
Hopkinton, MA 01748
Consent to Reference in Proxy Statement/Prospectus
Spring Bank Pharmaceuticals, Inc. (the “Company”) has filed a Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”). In connection therewith, I hereby consent, pursuant to Rule 438 of the Securities Act, to the reference to me in the proxy statement/prospectus/information statement included in such registration statement as a future member of the board of directors of the Company.
Sincerely, |
/s/ Geoffrey Race |
Name: Geoffrey Race |